Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoADAURA: neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in resectable EGFR-mutated NSCLC
MOH_2020-07-29_009171Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of osimertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AstraZeneca. Started Jul 2020; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2020-07-29_009171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-29_009171.